Selumetinib (Koselugo) is a MEK1/2 kinase inhibitor specifically indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged 1 year and older with neurofibromatosis type 1 (NF1).

How to Purchase Selumetinib (Koselugo)

Overseas Purchase

Patients may choose to consult and purchase the medication at hospital pharmacies or licensed drugstores in countries or regions where selumetinib has been approved for marketing.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchase and Use of Selumetinib (Koselugo)

Prescription Management Requirements

Selumetinib is a strictly controlled prescription drug and must be purchased with a valid prescription issued by a licensed physician.

Any sale of this drug without a prescription is a violation of pharmaceutical administration regulations.

Accurate Dosage Calculation

Standard dosage: The recommended dosage is 25 mg/m², administered orally twice daily.

Dosage adjustment for hepatic impairment: For patients with moderate hepatic impairment (Child-Pugh B), the dosage should be adjusted to 20 mg/m², administered orally twice daily; the safe dosage for patients with severe hepatic impairment (Child-Pugh C) has not been established.

Management of drug interactions: If concurrent use with strong or moderate CYP3A4 inhibitors or fluconazole is unavoidable, the dosage of selumetinib should be reduced accordingly.

Dosage Form-Specific Administration Guidelines

Capsule administration requirements: The capsules must be swallowed whole; they should not be opened, chewed, or crushed. They can be taken with or without food.

Oral granule administration guidelines: The granules should be mixed with approximately 1-3 teaspoons of smooth yogurt or fruit puree containing apples, bananas, pears, or strawberries, and administered within 30 minutes.

If the granules clump or adhere to the inside of the capsule shell, they must not be used, and the pharmacy should be contacted for a replacement.

The use of grapefruit juice, or juices, purees, or jams containing Seville oranges as the mixing medium is strictly prohibited.

Authentication of Selumetinib (Koselugo) Authenticity

Verification of Package Integrity

Verification of approval number: The official FDA approval number must be confirmed.

Manufacturer information: The drug is manufactured and distributed by AstraZeneca Pharmaceuticals LP.

Confirmation of storage conditions: Capsules should be stored at room temperature; oral granules require refrigerated transportation, and after receipt by the patient, they can be stored at room temperature but not exceeding 30°C.

Identification of Drug Appearance Characteristics

Capsule specification characteristics:

10 mg capsules: White to off-white, opaque hard capsules with a transparent sealing band, marked "SEL10" in black ink.

25 mg capsules: Blue, opaque hard capsules with a transparent sealing band, marked "SEL25" in black ink.

Oral granule specification characteristics:

5 mg granules: Capsules have a yellow cap and a white body, with "sel5" printed in black on the cap.

7.5 mg granules: Capsules have a pink cap and a white body, with "sel7.5" printed in black on the cap.